Support info of Preliminary study of efficacy and safety of Pembrolizumab and Nivolumab in treatment of advanced malignant tumors

中华放射肿瘤学杂志


	2019, Vol. 28(9): 687-691 DOI: 10.3760/cma.j.issn.1004-4221.2019.09.011

	Preliminary study of efficacy and safety of Pembrolizumab and Nivolumab in treatment of advanced malignant tumors
	Hou Lina¹,Dina·Suolitiken²,Ren Hua^3,4
	¹Medical abministration department,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China; ²Department of Internal Medicine-Oncology,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China; ³Department of Radiation Oncology,National Cancer Center,National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China; ⁴Department of Radiation Oncology,Shenzhen Hospital of Cancer Hospital,National Cancer Center,National Center for Oncology Clinical Medical Research,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China
	Received 2019-01-28 Revised null
	Supporting info


	null